Detalles de la búsqueda
1.
Convergent antibody responses to SARS-CoV-2 in convalescent individuals.
Nature
; 584(7821): 437-442, 2020 08.
Artículo
en Inglés
| MEDLINE | ID: mdl-32555388
2.
Combination therapy with anti-HIV-1 antibodies maintains viral suppression.
Nature
; 561(7724): 479-484, 2018 09.
Artículo
en Inglés
| MEDLINE | ID: mdl-30258136
3.
The RIO trial: rationale, design, and the role of community involvement in a randomised placebo-controlled trial of antiretroviral therapy plus dual long-acting HIV-specific broadly neutralising antibodies (bNAbs) in participants diagnosed with recent HIV infection-study protocol for a two-stage randomised phase II trial.
Trials
; 23(1): 263, 2022 Apr 05.
Artículo
en Inglés
| MEDLINE | ID: mdl-35382844
4.
Characterization of Co-Formulated High-Concentration Broadly Neutralizing Anti-HIV-1 Monoclonal Antibodies for Subcutaneous Administration.
Antibodies (Basel)
; 9(3)2020 Jul 29.
Artículo
en Inglés
| MEDLINE | ID: mdl-32751063
5.
A Combination of Human Broadly Neutralizing Antibodies against Hepatitis B Virus HBsAg with Distinct Epitopes Suppresses Escape Mutations.
Cell Host Microbe
; 28(2): 335-349.e6, 2020 08 12.
Artículo
en Inglés
| MEDLINE | ID: mdl-32504577
6.
Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals.
bioRxiv
; 2020 May 22.
Artículo
en Inglés
| MEDLINE | ID: mdl-32511384
7.
Safety, pharmacokinetics, and immunogenicity of the combination of the broadly neutralizing anti-HIV-1 antibodies 3BNC117 and 10-1074 in healthy adults: A randomized, phase 1 study.
PLoS One
; 14(8): e0219142, 2019.
Artículo
en Inglés
| MEDLINE | ID: mdl-31393868
8.
Safety and antiviral activity of combination HIV-1 broadly neutralizing antibodies in viremic individuals.
Nat Med
; 24(11): 1701-1707, 2018 11.
Artículo
en Inglés
| MEDLINE | ID: mdl-30258217
Resultados
1 -
8
de 8
1
Próxima >
>>